Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Uncontrolled Phase II Trial of HDAC-Inhibitor LBH589 in Patients With Chemo-refractory Metastatic Gastric Cancer Overexpressing Histone Deacetylases (HDACs) - CLBH589BDE03T

NCT01528501 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT01528501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01528501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Uncontrolled Phase II Trial of HDAC-Inhibitor LBH589 in Patients With Chemo-refractory Metastatic Gastric Cancer Overexpressing Histone Deacetylases (HDACs) - CLBH589BDE03T
Lead sponsor
Technical University of Munich
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2009
Completion date
Not reported
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric cancer